180 related articles for article (PubMed ID: 33374971)
21. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
[TBL] [Abstract][Full Text] [Related]
22. Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells.
Sun CY; Talukder M; Cao D; Chen CW
Front Pharmacol; 2022; 13():829759. PubMed ID: 35814226
[TBL] [Abstract][Full Text] [Related]
23. DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model.
Jimbo T; Hatanaka M; Komatsu T; Taira T; Kumazawa K; Maeda N; Suzuki T; Ota M; Haginoya N; Isoyama T; Fujiwara K
Oncotarget; 2019 Aug; 10(50):5152-5167. PubMed ID: 31497246
[TBL] [Abstract][Full Text] [Related]
24. CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer.
Wang L; Wu Y; Kang K; Zhang X; Luo R; Tu Z; Zheng Y; Lin G; Wang H; Tang M; Yu M; Zou B; Tong R; Yi L; Na F; Xue J; Yao Z; Lu Y
Transl Lung Cancer Res; 2024 May; 13(5):1032-1046. PubMed ID: 38854937
[TBL] [Abstract][Full Text] [Related]
25. CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer.
Li Y; Wang N; Huang Y; He S; Bao M; Wen C; Wu L
Cancer Genet; 2024 Jun; 284-285():34-42. PubMed ID: 38626533
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of resistance to osimertinib.
Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
[TBL] [Abstract][Full Text] [Related]
27. Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
Codony-Servat J; García-Roman S; Molina-Vila MÁ; Bertran-Alamillo J; Giménez-Capitán A; Viteri S; Cardona AF; D'Hondt E; Karachaliou N; Rosell R
J Thorac Oncol; 2018 Sep; 13(9):1324-1337. PubMed ID: 29751136
[TBL] [Abstract][Full Text] [Related]
28. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors.
Doval DC; Desai CJ; Sahoo TP
Indian J Cancer; 2019 Nov; 56(Supplement):S23-S30. PubMed ID: 31793439
[TBL] [Abstract][Full Text] [Related]
29.
Ma L; Chen R; Wang F; Ma LL; Yuan MM; Chen RR; Liu J
Ann Transl Med; 2019 May; 7(9):207. PubMed ID: 31205925
[TBL] [Abstract][Full Text] [Related]
30. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.
Huang Q; Wang Q; Li D; Wei X; Jia Y; Zhang Z; Ai B; Cao X; Guo T; Liao Y
J Exp Clin Cancer Res; 2019 Mar; 38(1):129. PubMed ID: 30876460
[TBL] [Abstract][Full Text] [Related]
31. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
32. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
33. Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib.
de Jager VD; Stigt JA; Niemantsverdriet M; Ter Elst A; van der Wekken AJ
NPJ Precis Oncol; 2024 May; 8(1):113. PubMed ID: 38778166
[TBL] [Abstract][Full Text] [Related]
34. Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in
Tozuka T; Noro R; Yoshida K; Takahashi S; Hirao M; Matsuda K; Kato Y; Nakamichi S; Takeuchi S; Matsumoto M; Miyanaga A; Kunugi S; Honda K; Adachi J; Seike M
JTO Clin Res Rep; 2024 Apr; 5(4):100668. PubMed ID: 38646155
[TBL] [Abstract][Full Text] [Related]
35.
Pan J; Xing J; Yu H; Wang Z; Wang W; Pan Y
Ann Transl Med; 2023 Mar; 11(6):252. PubMed ID: 37082696
[TBL] [Abstract][Full Text] [Related]
36. Compound 15c, a Novel Dual Inhibitor of EGFR
Chen G; Bao Y; Weng Q; Zhao Y; Lu X; Fu L; Chen L; Liu Z; Zhang X; Liang G
Front Pharmacol; 2019; 10():1533. PubMed ID: 31998131
[TBL] [Abstract][Full Text] [Related]
37. Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.
Onda N; Nakamichi S; Hirao M; Matsuda K; Matsumoto M; Miyanaga A; Noro R; Gemma A; Seike M
Cancer Sci; 2024 Jun; ():. PubMed ID: 38941131
[TBL] [Abstract][Full Text] [Related]
38. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
39. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.
Ninomiya K; Ohashi K; Makimoto G; Tomida S; Higo H; Kayatani H; Ninomiya T; Kubo T; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
Sci Rep; 2018 Jan; 8(1):1955. PubMed ID: 29386539
[TBL] [Abstract][Full Text] [Related]
40. The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET.
Yu D; Li Y; Sun KD; Gu J; Chen Z; Owonikoko TK; Ramalingam SS; Sun SY
Am J Cancer Res; 2020; 10(10):3316-3327. PubMed ID: 33163272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
